Vaccine Center Publications

  1. Salazar E, Perez KK, Ashraf M, Chen J, Castillo B, Christensen PA, et al. Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Convalescent Plasma. Am J Pathol. 2020 Aug;190(8):1680-1690. Epub 2020/05/27. PubMed PMID: 32473109; PMCID: PMC7251400.
  2. Hsieh CL, Goldsmith JA, Schaub JM, DiVenere AM, Kuo HC, Javanmardi K, et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science. 2020 Sep 18;369(6510):1501-1505. Epub 2020/07/23. PubMed PMID: 32703906; PMCID: PMC7402631.
  3. Salazar E, Kuchipudi SV, Christensen PA, Eagar T, Yi X, Zhao P, et al. Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization. J Clin Invest. 2020 Dec 1;130(12):6728-6738.PubMed PMID: 32910806; PMCID: PMC7685744.
  4. Weissman D, Alameh MG, de Silva T, Collini P, Hornsby H, Brown R, LaBranche CC, Edwards RJ, Sutherland L, Santra S, Mansouri K, Gobeil S, McDanal C, Pardi N, Hengartner N, Lin PJC, Tam Y, Shaw PA, Lewis MG, Boesler C, Şahin U, Acharya P, Haynes BF, Korber B, Montefiori DC. D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization. Cell Host Microbe. 2021 Jan 13;29(1):23-31.e4. doi: 10.1016/j.chom.2020.11.012. Epub 2020 Dec 1. PMID: 33306985; PMCID: PMC7707640.
  5. Luo Z, Girton AW, Heaton BE, Heaton NS. Engineered influenza virions reveal the contributions of non-hemagglutinin structural proteins to vaccine mediated protection. J Virol. 2021 Mar 3:JVI.02021-20. doi: 10.1128/JVI.02021-20. Epub ahead of print. PMID: 33658342.
  6. Voss WN, Hou YJ, Johnson NV, Delidakis G, Kim JE, Javanmardi K, et al. Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes. Science. 2021 Jun 4;372(6546):1108-1112. doi: 10.1126/science.abg5268. Epub 2021 May 4. PMID: 33947773; PMCID: PMC8224265.
  7. Froggatt HM, Burke KN, Chaparian RR, Miranda HA, Zhu X, Chambers BS, Heaton NS. Influenza A virus segments five and six can harbor artificial introns allowing expanded coding capacity. PLoS Pathog. 2021 Sep 27;17(9):e1009951. doi: 10.1371/journal.ppat.1009951. PMID: 34570829; PMCID: PMC8496794.
  8. Thornlow DN, Macintyre AN, Oguin TH, Karlsson AB, Stover EL, Lynch HE, Sempowski GD, Schmidt AG. Altering the Immunogenicity of Hemagglutinin Immunogens by Hyperglycosylation and Disulfide Stabilization. Front Immunol. 2021 Oct 7;12:737973. doi: 10.3389/fimmu.2021.737973. PMID: 34691043; PMCID: PMC8528956.
  9. Schaub JM, Chou CW, Kuo HC, Javanmardi K, Hsieh CL, Goldsmith J, et al. Expression and characterization of SARS-CoV-2 spike proteins. Nat Protoc. 2021 Nov;16(11):5339-56. Epub 20211005. PubMed PMID: 34611365